custom-header

The good ‘ol FDA in all it’s brilliance has done it Again! Another New Diet Pill

The good ‘ol FDA in all it’s brilliance has done it Again! Another New Diet Pill

Just yesterday the FDA approved another new diet pill for doctors to prescribe to obese patients.

Here’s the news article…

The new drug is called Belvig. The FDA had denied approval for this drug in  2010 when scientist showed concerns that the drug may actually cause tumors in people.

Tumors!

But just yesterday the FDA approved this drug  after “new information” was produced by the manufacturer.

wow

The studies show that this drug has helped obese people lose as much as 5% of their body  weight within a year.

That means that a 300 lbs obese woman can lose as much as 15 pounds in a year.

WTF?

Give me a 300 Lbs woman and I’ll help her lose 15  pounds in 2-3 weeks by two simple tweaks…

1. adding 15-20 minutes of walking to her lifestyle
2. and removing some starches from her diet

My point is this…

Here at The Body Clinic, Rapid Fat-loss and Muscle Toning Boot Camp we teach the  ultimate fat loss solution : lifestyle change, exercise, and good nutrition.

BUT the general public doesn’t care. All they’re going to see is the ten o’clock news
when the talking heads tell them that the FDA has approved a new weight loss pill.

Then they’re going to see the TV ads from this drug company touting the new weight loss drug and encouraging them to “ask your doctor about it”. The public is going to see hope in this drug. But we believe we have an ethical obligation to educate and enlighten our clients, prospects and community on this new drug and how like all other drugs that were
once approved and are now banned, this may  end up the same way.

And that ultimately the hope of losing 5% of your body weight within a year shouldn’t out weigh (pun intended)  the risk of side effects like potential TUMORS

Ed Williams
The Body Transformation Specialist
Tel: 501 600 4475
Click here to visit website

Leave a Reply

Your email address will not be published. Required fields are marked *